<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC4353274/table_2" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>TABLE 2</label>
  <p>Recommended oseltamivir regimens for prevention and treatment of adult patients with renal impairment (Tamiflu 
   <sup>®</sup> Product Monograph, 2014) 
  </p>
 </caption>
 <thead>
  <tr>
   <th valign="middle" align="left" rowspan="1" colspan="1" id="0-0-.">
    <b>Creatinine clearance</b>
   </th>
   <th valign="middle" align="left" rowspan="1" colspan="1" id="0-1-.">
    <b>Treatment for five days</b>
   </th>
   <th valign="middle" align="left" rowspan="1" colspan="1" id="0-2-.">
    <b>Prophylaxis (10–14 days)</b>
   </th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">&gt;60 mL/min</td>
   <td valign="top" align="left" rowspan="1" colspan="1">75 mg twice daily</td>
   <td valign="top" align="left" rowspan="1" colspan="1">75 mg once daily</td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">&gt;30–60 mL/min</td>
   <td valign="top" align="left" rowspan="1" colspan="1">30 mg suspension twice daily OR 30 mg capsule twice daily</td>
   <td valign="top" align="left" rowspan="1" colspan="1">30 mg once daily</td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">10–30 mL/min</td>
   <td valign="top" align="left" rowspan="1" colspan="1">30 mg once daily</td>
   <td valign="top" align="left" rowspan="1" colspan="1">30 mg on alternate days</td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">&lt;10 mL/min (renal failure)</td>
   <td valign="top" align="left" rowspan="1" colspan="1">Single 75 mg dose for the duration of illness</td>
   <td valign="top" align="left" rowspan="1" colspan="1">No data</td>
  </tr>
  <tr>
   <td rowspan="4" valign="top" align="left" colspan="1">Dialysis patients</td>
   <td valign="top" align="left" rowspan="1" colspan="1">Low-flux HD: 30 mg after each dialysis session</td>
   <td valign="top" align="left" rowspan="1" colspan="1">30 mg after alternate dialysis sessions</td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">High-flux HD: 75 mg after each dialysis session</td>
   <td valign="top" align="left" rowspan="1" colspan="1">No data</td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">CAPD dialysis: 30 mg once weekly</td>
   <td valign="top" align="left" rowspan="1" colspan="1">30 mg once weekly</td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">CRRT high-flux dialysis: 30 mg daily or 75 mg every second day</td>
   <td valign="top" align="left" rowspan="1" colspan="1">No data</td>
  </tr>
 </tbody>
 <tfoot>
  <p class="fn" charset="fn" id="tfn6-idmm-26-e5">
   <p>The following dosing regimen has been suggested for children based on limited data: In children &gt;1 year of age, after alternate hemodialysis (HD) sessions (7.5 mg for children weighing &gt;15 kg: 10 mg for children weighing 16–23 kg; 15 mg for children weighing 24–40 kg, and 30 mg for children weighing &gt; 40 kg). While this may provide a framework for guidance, it is strongly suggested that an infectious disease physician, a specialist in renal insufficiency or clinical pharmacist be consulted</p>
  </p>
 </tfoot>
</table>
